<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pharmjournal</journal-id><journal-title-group><journal-title xml:lang="ru">Разработка и регистрация лекарственных средств</journal-title><trans-title-group xml:lang="en"><trans-title>Drug development &amp; registration</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2305-2066</issn><issn pub-type="epub">2658-5049</issn><publisher><publisher-name>LLC «CPHA»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">pharmjournal-442</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>РЕГУЛЯТОРНЫЕ ВОПРОСЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REGULATORY ISSUES</subject></subj-group></article-categories><title-group><article-title>ПРОБЛЕМЫ СООТВЕТСТВИЯ ЦЕЛОСТНОСТИ ЗАПИСЕЙ ТРЕБОВАНИЯМ НАДЛЕЖАЩЕЙ ПРОИЗВОДСТВЕННОЙ ПРАКТИКИ. СООБЩЕНИЕ I. АКТУАЛЬНОСТЬ СОХРАНЕНИЯ ЦЕЛОСТНОСТИ ЗАПИСЕЙ</article-title><trans-title-group xml:lang="en"><trans-title>PROBLEMS OF CONFORMITY OF THE RECORDS INTEGRITY WITH THE REQUIREMENTS OF GOOD MANUFACTURING PRACTICE. REPORT 1. ACTUALITY OF THE RECORDS INTEGRITY CONSERVATION</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Осмоловская</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Osmolovskaya</surname><given-names>I. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зарочинская</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zarochinskaya</surname><given-names>O. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Емельянов</surname><given-names>М. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Emelianov</surname><given-names>M. O.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сомов</surname><given-names>Д. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Somov</surname><given-names>D. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ООО «ЛексФАРМА»<country>Россия</country></aff><aff xml:lang="en">LLC «LexPHARMA»<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>09</day><month>01</month><year>2019</year></pub-date><volume>0</volume><issue>2</issue><fpage>278</fpage><lpage>282</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Осмоловская И.А., Зарочинская О.В., Емельянов М.О., Сомов Д.В., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Осмоловская И.А., Зарочинская О.В., Емельянов М.О., Сомов Д.В.</copyright-holder><copyright-holder xml:lang="en">Osmolovskaya I.A., Zarochinskaya O.V., Emelianov M.O., Somov D.V.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmjournal.ru/jour/article/view/442">https://www.pharmjournal.ru/jour/article/view/442</self-uri><abstract><p>Целостность записей или целостность данных - самое «горячее» требование при оценке систем документации на соответствие требованиям надлежащей производственной практики (GMP). Именно на неё нацелен фокус внимания при проведении инспектирования фармацевтических предприятий. Эта статья первая из цикла статей, посвящённых данной теме. В ней объясняются причины важности сохранения целостности записей и приводятся примеры выявляемых несоответствий.</p></abstract><trans-abstract xml:lang="en"><p>Integrity of records or data integrity is the most «hot» requirement when assessing documentation systems for compliance with Good Manufacturing Practice (GMP). It's in the center of focus of attention during inspections of pharmaceutical companies. This article is the first of a series of articles devoted to this topic. In it explains the reasons for the importance of preserving the integrity of records and provides examples of identified deviations.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>целостность данных</kwd><kwd>записи</kwd><kwd>данные</kwd><kwd>инспекции</kwd></kwd-group><kwd-group xml:lang="en"><kwd>data integrity</kwd><kwd>records</kwd><kwd>data</kwd><kwd>inspections</kwd><kwd>GMP</kwd><kwd>FDA</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Приказ Минпромторга России от 14.06.2013 № 916 (ред. от 18.12.2015) «Об утверждении Правил над лежащей производственной практики» (зарегистрировано в Минюсте России 10.09.2013 № 29938).</mixed-citation><mixed-citation xml:lang="en">Приказ Минпромторга России от 14.06.2013 № 916 (ред. от 18.12.2015) «Об утверждении Правил над лежащей производственной практики» (зарегистрировано в Минюсте России 10.09.2013 № 29938).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">WHO Technical Report Series № 996. Annex 5 Guidance on good data and record management practices. 2016.</mixed-citation><mixed-citation xml:lang="en">WHO Technical Report Series № 996. Annex 5 Guidance on good data and record management practices. 2016.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">ИСО 8402. Управление качеством и обеспечение качества. Словарь.</mixed-citation><mixed-citation xml:lang="en">ИСО 8402. Управление качеством и обеспечение качества. Словарь.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">B. Unger. An Analysis Of FDA FY2016 Drug GMP Warning Letters. URL: https://www.pharmaceuticalonline.com/doc/an-analysisof-fda-fy-drug-gmp-warning-letters-0001 (дата обращения 27.04.2017).</mixed-citation><mixed-citation xml:lang="en">B. Unger. An Analysis Of FDA FY2016 Drug GMP Warning Letters. URL: https://www.pharmaceuticalonline.com/doc/an-analysisof-fda-fy-drug-gmp-warning-letters-0001 (дата обращения 27.04.2017).</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">B.W. Unger. Data integrity and data management for GxP regulated firms. URL: https://ungerconsulting.net/wp-content/uploads/2016/01/Data-Integrity-White-Paper-BLOG.pdf (дата обращения 27.04.2017).</mixed-citation><mixed-citation xml:lang="en">B.W. Unger. Data integrity and data management for GxP regulated firms. URL: https://ungerconsulting.net/wp-content/uploads/2016/01/Data-Integrity-White-Paper-BLOG.pdf (дата обращения 27.04.2017).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">J. Moldenhauer. Data Integrity Issues in Pharmaceutical Companies: Part 2. URL: http://www.ivtnetwork.com/article/dataintegrity-issues-pharmaceutical-companies-part (дата обращения 27.04.2017).</mixed-citation><mixed-citation xml:lang="en">J. Moldenhauer. Data Integrity Issues in Pharmaceutical Companies: Part 2. URL: http://www.ivtnetwork.com/article/dataintegrity-issues-pharmaceutical-companies-part (дата обращения 27.04.2017).</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">FDA: More Warning Letters for Lack of Data Integrity. URL: https://www.gmp-publishing.com/en/gmp-news/gmpaktuell/fda-warning-letters-data-integrity-ema-china-india.html (дата обращения 27.04.2017).</mixed-citation><mixed-citation xml:lang="en">FDA: More Warning Letters for Lack of Data Integrity. URL: https://www.gmp-publishing.com/en/gmp-news/gmpaktuell/fda-warning-letters-data-integrity-ema-china-india.html (дата обращения 27.04.2017).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">FDA усомнилась в качестве лекарственных средств, выпускаемых Mylan. URL: http://pharmjournal.ru/novosti-regulyatorov/fda-usomnilas-v-kachestve-lekarstvennyh-sredstv-vypuskaemyh-mylan (дата обращения 27.04.2017).</mixed-citation><mixed-citation xml:lang="en">FDA усомнилась в качестве лекарственных средств, выпускаемых Mylan. URL: http://pharmjournal.ru/novosti-regulyatorov/fda-usomnilas-v-kachestve-lekarstvennyh-sredstv-vypuskaemyh-mylan (дата обращения 27.04.2017).</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Warning Letter 320-16-12. URL: https://www.fda.gov/iceci/enforcementactions/warningletters/2016/ucm502347.htm(дата обращения 27.04.2017).</mixed-citation><mixed-citation xml:lang="en">Warning Letter 320-16-12. URL: https://www.fda.gov/iceci/enforcementactions/warningletters/2016/ucm502347.htm(дата обращения 27.04.2017).</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Warning Letter 320-17-01. URL: https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2016/ucm525640.htm (дата обращения 27.04.2017).</mixed-citation><mixed-citation xml:lang="en">Warning Letter 320-17-01. URL: https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2016/ucm525640.htm (дата обращения 27.04.2017).</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
